Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Receives $62.00 Consensus Price Target from Analysts
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has received a consensus rating of “Buy” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $62.00.
A number of research firms have recently commented on ARWR. Oppenheimer raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $58.00 price target on the stock in a research report on Friday, May 8th. B. Riley reaffirmed a “buy” rating and set a $57.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Sunday, May 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price target (down previously from $60.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 8th. SVB Leerink raised Arrowhead Pharmaceuticals from an “underperform” rating to a “market perform” rating and set a $29.00 price target on the stock in a research report on Tuesday, March 24th. Finally, Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, March 17th. They set a “neutral” rating and a $45.00 price objective for the company.
In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 36,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $35.83, for a total value of $1,289,880.00. Following the completion of the transaction, the director now directly owns 14,100 shares in the company, valued at $505,203. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Douglas B. Given sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $36.89, for a total value of $922,250.00. Following the completion of the transaction, the director now owns 155,925 shares of the company’s stock, valued at $5,752,073.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 184,815 shares of company stock valued at $7,045,730. 4.00% of the stock is owned by corporate insiders.
NASDAQ:ARWR traded down $0.59 during mid-day trading on Friday, hitting $44.51. The company had a trading volume of 728,000 shares, compared to its average volume of 1,199,202. Arrowhead Pharmaceuticals has a fifty-two week low of $19.51 and a fifty-two week high of $73.72. The business’s fifty day moving average is $37.47 and its two-hundred day moving average is $39.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.90 and a current ratio of 5.90. The firm has a market cap of $4.60 billion, a P/E ratio of 501.67 and a beta of 1.81.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.09). The business had revenue of $23.53 million for the quarter, compared to analyst estimates of $21.90 million. Arrowhead Pharmaceuticals had a return on equity of 2.61% and a net margin of 6.86%. Equities analysts forecast that Arrowhead Pharmaceuticals will post -0.44 earnings per share for the current year.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Further Reading: Derivative
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.